Pasireotide Phase 2 Trial for Post-Bariatric Hypoglycaemia Now Active, Not Recruiting

A clinical trial status update for pasireotide was recorded on September 17, 2026. The study, registered as NCT05928390 and titled "Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia," is a Phase 2 trial. Its current status is listed as active, not recruiting. This designation indicates the study is ongoing but is no longer enrolling new participants. Pasireotide is an approved compound being evaluated in this trial for its subcutaneous administration in patients experiencing hypoglycaemia following bariatric surgery. No outcome data, efficacy findings, or safety results have been reported as part of this status update. The trial record does not indicate when results might be posted or when the study is expected to conclude. Details on the trial design, patient population characteristics, and specific endpoints can be found in the official registration linked to this update. Readers interested in the broader context of pasireotide, including its approved uses and regulatory background, can consult the compound overview for additional information.